Nov. 22, 2023 Washington is scheduled to receive 7,700 50 mg and 600 100 mg Pfizer nirsevimab doses for the remainder of respiratory syncytial virus (RSV) season. The CDC released a Health Alert that provides guidance for healthcare providers. See the background section below for details. ACTIONS REQUESTED Immunize.org released a standing order template for this RSV season to ensure … Health Advisory: Nirsevimab supplies limited
Actions requested BE AWARE that on Oct. 3, 2023, U.S. Food and Drug Administration (FDA) authorized for emergency use a new adjuvanted (2023–2024) formulation of Novavax COVID-19 vaccine for people 12 years or older. BE AWARE that the FDA deauthorized the original Novavax COVID-19 vaccine. BE AWARE that the new adjuvanted (2023–2204) formulation of Novavax COVID-19 vaccine is … Health Advisory: FDA authorized new Novavax COVID-19 vaccine formulation
Actions requested BE AWARE that on Sept. 11, 2023, the U.S. Food and Drug Administration (FDA) approved and/or authorized for emergency use new, updated (2023–2024) COVID-19 vaccines from Moderna and Pfizer. Then, on Sept. 12, 2023, Centers for Disease Control and Prevention (CDC) recommended everyone 6 months or older get a new, updated (2023–2024) COVID-19 vaccine. … Health Advisory: New COVID-19 vaccines authorized, previous bivalent COVID-19 vaccines deauthorized
A person in Colorado tested positive for avian influenza A(H5N1) virus (H5 bird flu), Colorado Department of Public Health and Environment reported April 28, 2022. Centers for Disease Control and Prevention (CDC) confirmed it is the first U.S. case of H5 bird flu. The person was involved in the culling of poultry with presumptive H5 … 05/05/22 Health Advisory: Colorado person first U.S. case of H5 bird flu
Requested actions Be aware, on April 25, 2022, Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory about the availability and use of recommended COVID-19 therapies. It also advised against using unproven treatments that have known or potential harm. Follow National Institutes of Health (NIH) COVID-19 treatment guidelines and use … 04/27/22 Health Advisory: CDC Treatment Updates and ACIP discusses eligibility for second booster dose of COVID-19 vaccine
Requested actions Be aware, on March 29, 2022, Food and Drug Administration (FDA) amended its emergency use authorization (EUA) for Moderna COVID-19 booster dose vaccine. A new multi-dose vial is now available. It has a dark blue cap and a label with a purple border. Doses from this vial are 0.5 mL. Multi-dose vials are … 04/08/22 Health Advisory: COVID-19 Information for Providers
Requested actions Be aware, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup endorsed Food and Drug Administration’s (FDA’s) emergency use authorization (EUA) of a second booster dose of Pfizer or Moderna COVID-19 vaccines for specific groups. The EUA allows: A second booster dose of Pfizer COVID-19 vaccine at least … 03/30/22 Health Advisory: CDC endorses second booster dose of mRNA COVID-19 vaccine for certain groups
Requested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email … 03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … 02/25/22 Health Advisory: COVID-19 Updates for Providers
COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster … 02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
